Dysregulation in myelination mediated by persistent neuroinflammation: Possible mechanisms in chemotherapy-related cognitive impairment

Brain, Behavior, and Immunity

Volumn 35, Issue , 2014, Pages 23-32

  Briones, Teresita L ^a   Woods, Julie ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Corpus callosum; COX 2; IL 10; IL 1beta; TNF alpha

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; FLUOROURACIL; INTERLEUKIN 10; INTERLEUKIN 1BETA; METHOTREXATE; MYELIN; NS 393; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; FEMALE; MAZE TEST; MYELINATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TREATMENT DURATION; TREATMENT OUTCOME; ANIMAL; CHEMICALLY INDUCED; CORPUS CALLOSUM; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; METABOLISM; MYELINATED NERVE; PATHOLOGY; RANDOMIZATION; RECOGNITION; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COGNITION DISORDERS; CORPUS CALLOSUM; CYCLOPHOSPHAMIDE; CYTOKINES; FEMALE; FLUOROURACIL; INFLAMMATION; METHOTREXATE; NERVE FIBERS, MYELINATED; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECOGNITION (PSYCHOLOGY);

EID: 84888869456     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2013.07.175     Document Type: Article

References (49)

1. Abraham J., et al. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin. Breast Cancer 2008, 8:88-91.
2. Ahles T.A., Saykin A.J. Breast cancer chemotherapy-related cognitive dysfunction. Clin. Breast Cancer 2002, 3:S84-S90.
3. Aid S., Bosetti F. Targeting cyclooxygenases-1 and -2 in neuroinflammation: therapeutic implications. Biochimie 2011, 93:46-51.
4. Barker G.R.I., Warburton E.C. When is the hippocampus involved in recognition memory?. J. Neurosci. 2011, 31:10721-10731.
5. Baumann N., Pham-Dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol. Rev. 2001, 81:871-927.
6. Block M.L., Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 2005, 76:77-98.
7. Boykoff N., Moieni M., Subramanian S.K. Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J. Cancer Survivor 2009, 3:223-232.
8. Briones T.L., Darwish H. Vitamin D mitigates age-related cognitive decline through the modulation of pro-inflammatory state and decrease in amyloid burden. J. Neuroinflam. 2012, 9:244.
9. Briones T.L., Woods J. Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications. BMC Neurosci. 2011, 9:124.
10. Briones T.L., et al. Amelioration of cognitive impairment and changes in microtubule-associated protein 2 after transient global cerebral ischemia are influenced by complex environment experience. Behav. Brain Res. 2006, 168:261-271.
11. Briones T.L., Rogozinska M., Woods J. Environmental experience modulates ischemia-induced amyloidogenesis and enhances functional recovery. J. Neurotrauma 2009, 24:613-625.
12. Briones T.L., Rogozinska M., Woods J. Modulation of ischemia-induced NMDAR1 activation by environmental enrichment decreases oxidative damage. J. Neurotrauma 2011, 28:2485-2492.
13. Campagnoni A.T., Maeklin W.B. Cellular and molecular aspects of myelin basic protein gene expression. Mol. Neurobiol. 1988, 2:41-89.
14. Castellon S.A., Ganz P.A. Neuropsychological studies in breast cancer: in search of chemobrain. Breast Cancer Res. Treat. 2009, 116:125-127.
15. Correa D.D., Ahles T.A. Cognitive adverse effects of chemotherapy in breast cancer patients. Curr. Opin. Support Palliat. Care 2007, 1:57-62.
16. de Ruitner M.B., et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum. Brain Mapp. 2011, 32:1206-1219.
17. Deprez S., et al. Chemotherapy-induced structral changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum. Brain Mapp. 2011, 32:480-493.
18. Dietrich J., et al. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J. Biol. 2006, 5. 22.1-23.
19. Finnie J.W. Neuroinflammation: beneficial and detrimental effects after traumatic brain injury. Inflammopharmacology 2013, PMID: 23296919.
20. Gold B.T., et al. Age-related slowing of task switching is associated with decreased integrity of frontoparietal white matter. Neurobiol. Aging 2010, 31:512-522.
21. Han R., et al. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J. Biol. 2008, 7:12.
22. Hodgson K.D., et al. A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev. 2013, 39:297-304.
23. Inagaki M., et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007, 109:146-156.
24. Janelsins M.C., et al. Cognitive difficulties, fatigue, and sleep in cancer patients at pre-chemotherapy, post-chemotherapy, and at three months follow-up. Ann. Behav. Med. 2010, 39.
25. Janelsins M.C., et al. An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin. Oncol. 2011, 38:431-438.
26. Kennedy K.M., Rax N. Aging white matter and cognition: differential effects of regional variations in diffusion properties on memory, executive functions, and speed. Neuropsychologia 2009, 47:916-927.
27. Kesler S.R., et al. Regional brain activation during verbal declarative memory in metastatic breast cancer. Clin. Cancer Res. 2009, 15:6665-6673.
28. Koppelmans V., et al. Incidental findings on brain magnetic resonance Imaging in long-term survivors of breast cancer treated with adjuvant chemotherapy. Eur. J. Cancer 2011, 10.1016/j.ejca.2011.06.026.
29. Koppelmans V., et al. Global and focal white matter integrity in breast cancer survivors 20 years afer adjuvant chemotherapy. Hum. Brain Mapp. 2012, 1-11.
30. Lu P.H., et al. Age-relaed slowing in cognitive processing speed is associated with myelin integroty in a very healthy elederly sample. J. Clin. Exp. Neuropsychol. 2011, 33:1059-1068.
31. Lu P.H., et al. Myelin breakdown mediates age-related slowing in cognitive processing speed. Brain Cogn. 2013, 81:131-138.
32. Lucin K.M., Wyss-Coray T. Immune acivation in brain aging and neurodegeneration: too much or too little?. Neuron 2009, 64:110-122.
33. McDonald B.C., et al. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res. Treat. 2010, 123:819-828.
34. Mumby D.G., et al. Hippocampal damage and exploratory preferences in rats: memory for objects, places, and context. Learn Mem. 2002, 9:49-57.
35. Nelson C.J., Nandy N., Roth A.J. Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliat. Support Care 2007, 5:273-280.
36. Pepicelli O., et al. Cyclo-oxygenase-1 and -2 differently contribute to prostaglandin E2 synthesis and lipid peroxidation after in vivo activation of N-methyl-D-aspartate receptors in rat hippocampus. J. Neurochem. 2005, 93:1561-1567.
37. Phillis J.W., Horrocks L.A., Farooqui A.A. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res. Rev. 2006, 52:201-243.
38. Reid-Arndt S.A. Breast cancer and "chemobrain": the consequences of cognitive difficulties following chemotherapy and potential for recovery. Mol. Med. 2009, 106:127-131.
39. Sakane T., et al. Transnasal delivery of 5-fluorouracil to the brain in the rat. J. Drug Target. 1999, 7:233-240.
40. Schachner M., Kim S.K., Zehnle R. Developmental expression in central and peripheral nervous system of oligodendrocyte cell surface antigens (O antigens) recognized by monoclonal antibodies. Dev. Biol. 1981, 83:328-338.
41. Seigers R., et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methothrexate in the rat. Behav. Brain Res. 2008, 186:168-175.
42. Seigers R., et al. Inhibition of hippocampal cell proliferation by methotrexate in rats is not potentiated by the presence of a tumor. Brain Res. Bull. 2010, 81:472-476.
43. Seigers R., et al. Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release. Behav. Brain Res. 2010, 207:265-272.
44. Silverman D.H., et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survisors 5-10 years after chemotherapy. Breast Cancer Res. Treat. 2007, 103:303-311.
45. Simo M., et al. Chemobrain: a systematic review of structural and functional neuroimaging studies. Beurosci. Biobehav. Rev. 2013, 37:1311-1321.
46. van der Knapp L.J., van der Ham I.J.M. How does the corpus callosum mediate interhemispheric transfer? A review. Behav. Brain Res. 2011, 223:211-221.
47. Weiss B. Chemobrain: a translational challenge for neurotoxicology. Neurotoxicology 2008, 29:891-898.
48. Woodcock T., Morganti-Kossman M.C. The role of markers of inflammation in traumatic brain inury. Front. Neurol. 2013, 4:18.
49. Yang H., Chen C. Cyclooxygenase-2 in synaptic signaling. Curr. Pharm. Des. 2008, 14:1443-1451.